Hormone · Investigational
GHRP-1
No lawful US pathway
01 · Overview
Growth Hormone Releasing Peptide-1 is a synthetic heptapeptide (seven amino acids) belonging to the growth hormone secretagogue family (PMID 8279223). It acts on the growth hormone secretagogue (ghrelin) receptor to stimulate growth hormone release from the anterior pituitary.
GHRP-1 was one of an early series of small synthetic growth hormone releasing peptides and has been used mainly as a research tool.
02 · Research summary & key findings
In short but otherwise healthy children and adolescents, an intravenous bolus of GHRP-1 produced a rise in growth hormone peaking at 15 to 30 minutes, while most patients with pituitary insufficiency did not respond (PMID 8279223). In a randomized, placebo-controlled study, GHRP-1 elicited growth hormone responses in nonpregnant and postpartum women, with lower and slower responses during lactation (PMID 9435424). The compound has not advanced to pivotal clinical trials.
03 · Regulatory status
GHRP-1 is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
No lawful pathway today
GHRP-1 is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
See the 13 FDA-approved compounds in Hormone
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for hormone optimization?
GHRP-1 is an investigational compound, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on hormone optimization, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Subcutaneous injection
- Intravenous
References
- [1]Growth hormone-releasing activity of growth hormone-releasing peptide-1 (a synthetic heptapeptide) in children and adolescents Acta Endocrinol (Copenh), 1993. PMID 8279223
- [2]Postpartum hyperprolactinemia and hyporesponsiveness of growth hormone (GH) to GH-releasing peptide J Clin Endocrinol Metab, 1998. PMID 9435424
Primary literature
- PubMed: "GHRP-1"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "GHRP-1"
Registered interventional and observational studies, including status and phase.
- PubChem: "GHRP-1"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Hormone
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.